Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Health IT Homepage

Want to reduce readmissions? Let’s start with keeping patients healthier Insights from Robin Hill, chief clinical officer at Vivify Health

Decision support software could reduce scans by 6 percent: MIT researchers Prevent overuse of powerful and costly imaging exams

CMS to add more telehealth benefits to Medicare Advantage plans Aiming for greater flexibility, lower costs

Fredrik Palm ContextVision appoints new CEO

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

Three recommendations to better understand HIPAA compliance Approximately 70 percent of organizations are not HIPAA compliant

Researchers orchestrate malware attack to expose imaging vulnerabilities Deceived radiologists and AI algorithms into misdiagnoses

How hyper-targeting patient communications can improve medication adherence Providing specific messages can make a world of difference

Sound Imaging launches MR patient motion and detection system, SAMM MD Reduces repeat scans, prevents interruption to workflow

Where are your patients going? Keeping patients from switching to a new provider is good business and good medicine

Elekta is combining the capabilities
of its MOSAIQ Oncology Information
System with the the AI and cloud
computing abilities of IBM's Watson
for Oncology

With IBM, Elekta to bring AI to radiotherapy

by John R. Fischer , Staff Reporter
Elekta is throwing its health IT hat into the artificial intelligence ring by pairing up with IBM Watson Health in a collaboration that combines the capabilities of Elekta’s MOSAIQ Oncology Information System and IBM’s Watson for Oncology platform.

The agreement sets the foundation for an interface utilizing Watson for Oncology as a clinical decision support solution with MOSAIQ to enhance treatment planning and enable evidence-based treatment recommendations for any patient no matter their location. It also makes Elekta the first radiation therapy company to combine capabilities of conventional health information systems with artificial intelligence and cognitive cloud computing.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

“This interface will be able to upload patient data, including the lab reports, the documents and diagnoses, and patient information directly from MOSAIQ into the Watson products,” Andrew Wilson, vice president of global marketing-software at Elekta, told HCB News. “From a physician’s perspective, it will become a relatively seamless operation. The data will be uploaded with a click, and information will be ready in Watson for it to build analysis. It will mean that when sites are configured with MOSAIQ and Watson, they’ll have this functionality."

The desire for data-driven, evidence-based cancer care has fueled the growth and availability of medical information to the point where it is expected to double every 73 days by 2020, outpacing the ability of humans to keep up with its proliferation.

Watson for Oncology summarizes key medical attributes of patients and provides oncologists with information to help them choose treatment options based on training by oncologists from Memorial Sloan Kettering Cancer Center (MSK), where Watson for Oncology was developed by IBM as part of a collaboration.

It also ranks treatment options and links to peer-reviewed studies curated by MSK, while providing access to nearly 15 million pages of text to guide physicians on different treatment options, with information derived from more than 300 medical journals and more than 200 textbooks.

Its combination with Elekta’s MOSAIQ will enable users to access an exhaustive amount of data that Watson has been able to provide on a global scale, and utilize MSK protocols.

“I think it absolutely redefines that treating cancer is reliably data-driven and requires evidence-based outcomes,” said Wilson. “With the exponential change that exists in the amount of information that’s available, while clinicians have a really strong standard in terms of training and education, having something like the physician support tools created by Watson to help make those decisions for them provides them an additional level of confidence so that they can basically confirm with Watson that they can make the right decisions for the patient.”

The interface will follow an FHIR protocol which is an HL7 industry standard.

Sales are set to begin in early 2018 with plans to distribute both solutions in the U.S., Brazil, India, Australia and certain major European and Asian markets.

Health IT Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.